Dental group receives takeover bid at a handy premium

This ASX-listed dental group looks likely to be taken over under a new offer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Pacific Smiles has received a takeover offer at a 37.5% premium.
  • An independent board committee has recommended shareholders accept the offer.
  • The bidder already owns almost 90% of the company's shares.

ASX-listed dental company Pacific Smiles Group Ltd (ASX: PSQ) has received a takeover bid from its majority shareholder, Genesis Bidco, at a 37.5% premium to the share price prior to the bid announcement.

The bidder, which currently owns 89.27% of Pacific Smiles, has offered $2.20 in cash for each share in the company it doesn't already own, compared with the closing price on Thursday of $1.60.

Pacific Smiles has established an independent committee to assess the bid, and that committee has unanimously recommended that shareholders accept the offer in the absence of a superior bid.

The committee has also commissioned an independent expert's report into the bid, to assess whether it is fair and reasonable; however, the company said Deloitte Corporate Finance, which would produce the report, at this stage concluded that the bid was in the best interests of shareholders.

The independent board committee has carefully considered the offer to assess whether it is in the best interest of Pacific Smiles shareholders other than Genesis Bidco and its associates and, having completed that work, unanimously recommends that shareholders accept the offer.

The takeover offer is unconditional and is not subject to regulatory approval.

Businesswoman holds hand out to shake.

Image source: Getty Images

Takeover virtually a fait accompli

The company stated in its ASX announcement on Friday that a competing bid was highly unlikely, given the dominance of the majority shareholder and the fact that the next largest shareholder held a 10.01% stake in the company.

This meant the remaining shareholders own just 0.72% of Pacific Smiles.

The company in August reported an underlying profit of $11.8 million for FY25, up from $8.5 million the previous year, on revenue of $196 million, up 9.1%.

The company spent $11.6 million during the year responding to two previous takeover offers from Genesis Bidco and another vehicle, NDC Bidco, with the money allocated to legal fees and external consulting.

The earlier Genesis takeover offer was launched in July last year and offered $1.90 per share for the company, or a combination of cash and stock in the bidding company.

Pacific Smiles shareholders voted against the NDC proposal at a meeting held in August last year. NDC then walked away from the bidding process, and Genesis relaunched its offer and started building up its stake in the company.

Pacific Smiles shares are thinly traded, with an average trade volume of about 1500 shares.

The company was valued at $258.6 million at the close of trade on Thursday.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of young people celebrate and party outside.
Healthcare Shares

If I'd invested $5,000 in 4DMedical shares 12 months ago, guess how much I'd have now!

Can the company's share price keep accelerating even higher? Here's what analysts tip for the next 12 months.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 reasons I'd buy CSL shares in FY27

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

CSL shares jump 15%: Is it time to start buying the beaten-down biotech stock?

CSL shares have climbed 7% higher over the past week alone.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why is this ASX biotech rocketing more than 20%?

A deal potentially worth hundreds of millions has been struck.

Read more »

Young girl shows hearing aid while smiling.
Healthcare Shares

3 reasons to buy Cochlear shares in June

After a brutal sell-off, the stock may be gearing up for a recovery.

Read more »

patient with doctor, medical company, medical insurance
Cheap Shares

CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade

The ASX 200 healthcare giant is down more than 60% since August 2025.

Read more »

Falling pills in a blue background.
Healthcare Shares

Sigma Healthcare shares are surging. What does Macquarie say they're worth?

A possible deal has fallen over, which investors appear to like.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

CSL shares: bargain or value trap?

Let's see if now is a good time to buy this biotech giant's shares.

Read more »